

Patient: DOE, JANE
Date of Birth: Feb 02, 1944
Sex: M

Physician: TEST
NPI #:1154
Practice: IHM

Date Collected: Mar 21, 2022
Date Received: Mar 23, 2022
Date Processed: Mar 23, 2022
Specimen type/Source: Eswab
Sample ID: 2063302

1. About This Report

This Wound Panel Report assesses skin, soft tissue and deep wound infection and consists of molecular identification tests for microorganisms and genes of antibiotic resistance implicated in complex wound management.

2. Molecular Diagnostic Results

SST

- <i>A. baumannii</i>	Negative
- <i>B. fragilis</i>	Negative
- <i>B. henselae</i>	Negative
- <i>C. albicans</i>	Negative
- <i>C. freundii</i>	Negative
- <i>C. parapsilosis</i>	Negative
- <i>C. perfringens</i>	Negative
- <i>C. tropicalis</i>	Negative
- <i>E. cloacae</i>	Negative
- <i>E. coli</i>	Negative
- <i>E. faecalis</i>	Negative
- <i>E. faecium</i>	Negative
- <i>Herpes simplex 1</i>	Negative
- <i>Herpes simplex 2</i>	Negative
- <i>K. oxytoca</i>	Negative
- <i>K. pneumoniae</i>	Negative
- <i>M. abscessus</i>	Negative
- <i>P. aeruginosa</i>	Negative
- <i>P. mirabilis</i>	Negative
- <i>Prevotella spp.</i>	Negative
+ <i>S. agalactiae</i>	Positive
+ <i>S. aureus</i>	Positive
- <i>S. maltophilia</i>	Negative
- <i>S. marcescens</i>	Negative
- <i>S. pyogenes</i>	Negative

Antibiotic Resistance

- CTX-M group 1	Negative
- <i>ErmA</i>	Negative
- <i>ErmB</i>	Negative
- KPC	Negative
+ <i>mecA</i>	Positive
- NDM	Negative
- <i>sul 1</i>	Negative
- <i>vanA1</i>	Negative
- <i>vanB</i>	Negative

2063302 - DOE, JANE - Reported Mar 23, 2022

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen. Portions © 2014-2022 Coriell Life Sciences Inc.

3. Antibiotic Treatment Options

The following table shows common treatment options for organisms assayed as present in this sample, combined with any positive or negative assayed resistance markers. "T" indicates a treatment option; "T:R" indicates a treatment option that may be affected by the detected resistance marker(s).

	<i>S. agalactiae</i>	<i>S. aureus</i>	Resistances
doxycycline (Broad-spectrum tetracycline)	-	T	Not assayed
† ceftaroline (Cephalosporines)	-	T:R	mecA
† cephalexin (Cephalosporins)	T:R	T:R	mecA
† cefazolin (Cephalosporins)	-	T:R	mecA
† amoxicillin-clavulanate (Extended-Spectrum-Beta lactam)	-	T:R	mecA
oritavancin (Glycopeptides)	-	T	Not assayed
dalbavancin (Glycopeptides)	-	T	Not assayed
clindamycin (Lincomycin)	T	T	Not assayed
† penicillin (Narrow-Spectrum-Beta lactam)	T:R	-	mecA
† dicloxacillin (Narrow-Spectrum-Beta lactam)	-	T:R	mecA
† oxacillin (Narrow-Spectrum-Beta lactam)	-	T:R	mecA
linezolid (Oxazolidinone)	-	T	Not assayed
tedizolid (Oxazolidinone)	-	T	Not assayed
† nafcillin (Penicillins)	T:R	T:R	mecA
daptomycin (Peptide)	-	T	Not assayed
sulfamethoxazole/trimethoprim (Sulfonamides)	-	T	Negative

2063302 - DOE, JANE - Reported Mar 23, 2022

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen. Portions © 2014-2022 Coriell Life Sciences Inc.

Wound Panel Report



	<i>S. agalactiae</i>	<i>S. aureus</i>	Resistances
vancomycin (<i>Vancomycin</i>)	-	T	Negative

† Consider alternate treatment due to detected resistance marker(s).

2063302 - DOE, JANE- Reported Mar 23, 2022

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen. Portions © 2014-2022 Coriell Life Sciences Inc.

Powered by:
CORIELL
LIFE SCIENCES

Pg. 3 of 5

Wound Panel Report



Wound Organism Results

	Assay	Presence
A. baumannii	Acinetobacter baumannii	
B. fragilis	Bacteroides fragilis	
B. henselae	Bartonella henselae	
C. albicans	Candida albicans	
C. freundii	Citrobacter freundii	
C. parapsilosis	Candida parapsilosis	
C. perfringens	Clostridium perfringens	
C. tropicalis	Candida tropicalis	
CTX-M group 1	Extended-Spectrum-Betalactamase	
E. cloacae	Enterobacter cloacae	
E. coli	Escherichia coli	
E. faecalis	Enterococcus faecalis	
E. faecium	Enterococcus faecium	
ErmA	Macrolide resistance (ErmA)	
ErmB	Macrolide resistance (ErmB)	
Herpes simplex 1	Herpes simplex 1	
Herpes simplex 2	Herpes simplex 2	
K. oxytoca	Klebsiella oxytoca	
K. pneumoniae	Klebsiella pneumoniae	
KPC	Carbapenem resistance (KPC)	
M. morganii	Morganella morganii	
mecA	Methicillin resistance (mecA)	Detected
NDM	Carbapenem resistance (NDM)	
P. aeruginosa	Pseudomonas aeruginosa	
P. mirabilis	Proteus mirabilis	
Prevotella spp.	Prevotella spp.	
S. agalactiae	Streptococcus agalactiae	Detected

2063302 - DOE, JANE - Reported Mar 23, 2022

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen. Portions © 2014-2022 Coriell Life Sciences Inc.

Wound Panel Report



	Assay	Presence
S. aureus	Staphylococcus aureus	Detected
S. maltophilia	Stenotrophomonas maltophilia	
S. marcescens	Serratia marcescens	
S. pyogenes	Streptococcus pyogenes	
sul 1	Sulfonamide 1 resistance (sul 1)	
vanA1	Vancomycin resistance (vanA1)	
vanB	Vancomycin resistance (vanB)	

Report Signed by: Alisa Turner March 23, 2022 05:00:00 PM

In the case that no pathogenic microorganisms are identified by this assay, the presence of antibiotic resistance genes may be attributable to non-pathogenic microorganisms or possible rarely-occurring pathogenic microorganisms that SMA Specialty Medical Lab has not examined in its assay. Clinical correlation is suggested.

Limitation: An absence of detection does not imply the absence of microorganisms other than those listed or does not exclude the possibility that the target sequence is present below the limit of detection. The Wound Panel Report does not take into consideration patient history, drug-drug interactions, drug sensitivity, and/or allergies. It is the responsibility of the physician to determine appropriate drug and dosing choices based on all available data.

Methodology: Array based assays simultaneously detect a wide array of bacteria, yeast, viruses, and antibiotic resistance genes at analytical sensitivity and specificity >99%.

Disclaimer: These tests were developed and characterized by SMA Specialty Medical Lab and interpreted by Coriell Life Sciences, 4747 South Broad Street, Building 101, Suite 222, Philadelphia, PA 19112. The tests in this Wound Panel Report panel have not been approved by the Food and Drug Administration. The FDA has determined that such approval is not necessary, provided that the laboratory both (1) maintains its good standing as a clinical testing laboratory with all mandatory accrediting bodies, and (2) continually demonstrates that its testing protocols and procedures achieve a high degree of analytical accuracy.

Laboratory Certification: CLIA # 39D0987158

Laboratory Director: Janusz J. Godyn, MD, FCAP

2063302 - DOE, JANE - Reported Mar 23, 2022

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history, and current treatment regimen. Portions © 2014-2022 Coriell Life Sciences Inc.

Powered by:
CORIELL
LIFE SCIENCES

Pg. 5 of 5